Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

KY-02327

Copy Product Info
😃Good
Catalog No. T39508Cas No. 2093407-25-9

KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differentiation.

KY-02327

KY-02327

Copy Product Info
😃Good
Purity: 97.04%
Catalog No. T39508Cas No. 2093407-25-9
KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differentiation.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$231In StockIn Stock
5 mg$398In StockIn Stock
10 mg$592In StockIn Stock
25 mg$947In StockIn Stock
50 mg$1,280In StockIn Stock
100 mg$1,730In Stock-
500 mg$3,470InquiryInquiry
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:97.04%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differentiation.
In vitro
KY-02327 treatment (1-10 μM; 2 days) on MC3T3E1 cells, a murine pre-osteoblast cell line, enhances β-catenin protein level and Runx2, as well as nuclear β-catenin accumulation, in a dose-dependent manner [1]. Additionally, KY-02327 (1-10 μM) elevates the mRNA expression of osteoblast differentiation markers, collagen 1a (Col1a) and osteocalcin (OCN) [1].
In vivo
KY-02327 (20 mg/kg; p.o.; administered for 5 consecutive days each week for 4 weeks) effectively mitigates bone loss in an ovariectomized (OVX) mouse model, demonstrating its potential for osteoporosis treatment by stimulating bone growth[1]. In this study, 8-week-old female BL6 mice were treated following the specified regimen, resulting in increased bone formation in the femur, confirmed by calcein labeling, compared to vehicle-treated OVX mice.
Chemical Properties
Molecular Weight373.45
FormulaC20H27N3O4
Cas No.2093407-25-9
SmilesC(C(NCCN1CCCCC1)=O)N2C=3C(C=C2C(OCC)=O)=CC(O)=CC3
Relative Density.1.27 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 100 mg/mL (267.77 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.71 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.6777 mL13.3887 mL26.7773 mL133.8867 mL
5 mM0.5355 mL2.6777 mL5.3555 mL26.7773 mL
10 mM0.2678 mL1.3389 mL2.6777 mL13.3887 mL
20 mM0.1339 mL0.6694 mL1.3389 mL6.6943 mL
50 mM0.0536 mL0.2678 mL0.5355 mL2.6777 mL
100 mM0.0268 mL0.1339 mL0.2678 mL1.3389 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy KY-02327 | purchase KY-02327 | KY-02327 cost | order KY-02327 | KY-02327 chemical structure | KY-02327 in vivo | KY-02327 in vitro | KY-02327 formula | KY-02327 molecular weight